TNF-alpha Antibody

TNF-alpha Antibody Datasheet

TNF-alpha Antibody Product Information

• Immunogen: Recombinant Canine TNF-alpha Protein (Catalog #70003-DNAE)
• Antibody Type: Mouse Monoclonal Antibody ( Mouse mAb Service Platform )
• Clone ID: 1F8D10
• Ig Type: Mouse IgG1
• Formulation: 0.2 μm filtered solution in PBS with 5% trehalose
• Preparation: This antibody was produced from a hybridoma resulting from the fusion of a mouse myeloma with B cells obtained from a mouse immunized with purified, human cell-derived, recombinant Canine TNF-alpha (rCanine TNF-alpha; Catalog #70003-DNAE; NP_001003244.4; Val 77-Leu 233). The IgG fraction of the cell culture supernatant was purified by Protein A affinity chromatography.

TNF-alpha Antibody Usage Guide

• Specificity: Canine TNF-alpha
• No cross-reactivity in ELISA with
  

  Human TNF-α

  Mouse TNF-α

  Rat TNF-α

  E.coli cell lysate

• Western blot: This antibody can be used at 1-2 μg/mL with the appropriate secondary reagents to detect Canine TNFα in WB.
• Direct ELISA: This antibody can be used at 0.5-1 μg/mL with the appropriate secondary reagents to detect Canine TNFα. The detection limit for Canine TNFα is approximately 0.625 ng/well.
• Storage: This antibody can be stored at 2℃-8℃ for one month without detectable loss of activity. Antibody products are stable for twelve months from date of receipt when stored at -20℃ to -70℃. Preservative-Free.
  Sodium azide is recommended to avoid contamination (final concentration 0.05%-0.1%). It is toxic to cells and should be disposed of properly. Avoid repeated freeze-thaw cycles.

TNF-alpha Antibody Background

Canine tumor necrosis factor alpha (TNFa), also known as cachectin and TNFSF1A, is the prototypic cytokine of the the TNF superfamily, and is a multifunctional molecule involved in the regulation of a wide spectrum of biological processes including cell proliferation, differentiation, apoptosis, lipid metabolism, and coagulation. TNFa is produced mainly by macrophages, and large amounts of this cytokine are released in response to lipopolysaccharide, other bacterial products, and Interleukin-1 (IL-1). TNFa is primarily produced as a 26 kDa type II transmembrane protein arranged in stable homotrimers, and a 55 kDa soluble trimeric form of TNFa is released via proteolytic cleavage by the metalloprotease TACE/ ADAM17. Two receptors mediating the TNFa function have been identified, the ubiquitous TNFRI from which most signaling are derived, and the hematopoietic cell-restricted TNFRII. Upon the TNFa trimers binding, TNF receptors also form trimers, undergo a conformational change, and enable the adaptor protein TRADD to bind to the death domain, and thus initiates the signal pathways such as the NF-kB, Jak/STAT, and the MAPK pathways, as well as the death signaling. As a major mediator of apoptosis, inflammation and immunity, TNFa has been implicated in the pathogenesis of a variety of diseases including autoimmune diseases, insulin resistance, and cancer.

References

1. Guo, DQ. et al., 1998, J. Immunol. 160: 2742-50.
2. Black, RA. et al., 1997, Nature. 385: 729-33.
3. Chen, G. et al., 2002, Science. 296: 1634-5.
4. Locksley, RM. et al., 2001, Cell. 104: 487-501.
5. Sheng, WS. et al., 2005, J. Leukoc. Biol. 78: 1233-41.
6. Horssen, RV. e t al., 2006, Oncologist. 11: 397-408.
7. Marchetti, L. et al., 2004, J. Biol. Chem. 279: 32869-81.